Dry Eye
Conditions
Brief summary
Multi-centre, international, non-interventional, prospective survey
Detailed description
To assess after 84 days, on a large scale patient population, the evaluation of ocular surface diseases and the satisfaction of dry eye disease (DED) treatment naïve patients or those who had to switch for tolerance, dissatisfaction or efficacy reasons to Thealoz® Duo.
Interventions
DEVICEThealoz Duo
Non applicable
Sponsors
Iris Pharma
Laboratoires Thea
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* All dry eye patients who require artificial tears or need to change their current artificial tears for any reason (i.e. due to dissatisfaction or low efficacy, etc…) * Outpatients of either sex, aged at least 18 years * Patients informed of the objectives of the survey and agreeing to participate.
Exclusion criteria
* Use of cyclosporine, lifitegrast, tacrolimus, sirolimus within last 3 months and during the survey * Use of topical ophthalmological treatments (glaucoma, etc…) * Use of lacrimal plugs * Ocular surgery in the last 12 months * Concomitant use of corticosteroids * Concomitant use of autologous serum or any blood derivatives * Severe blepharitis * Severe dry eye associated to * Eyelid malposition * Corneal dystrophy * Ocular neoplasia * Sjogren syndrome * Any systemic pathologies * Pregnancy/lactation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OSDI | 84 days | Change from baseline for patient symptoms using the ocular surface disease index (OSDI©) questionnaire at Day 84. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability. |
Countries
United Kingdom
Outcome results
None listed